Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial-Reference-Cited by-同舟云学术

Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial

Published:2013-10 Issue:4 Volume:168 Page:4076-4080
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

DiNicolantonio James J.,Tomek Ales

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference13 articles.

1. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin;N Engl J Med,2009

2. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified;Serebruany;Thromb Haemost,2011

3. Drug approval package: Brilinta (tricagrelor) tablets;U.S. Food and Drug Administration,2013

4. Drug approval package: Brilinta (tricagrelor) tablets;U.S. Food and Drug Administration,2013

5. Ticagrelor FDA, approval issues revisited;Serebruany;Cardiology,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet agents for chronic kidney disease;Cochrane Database of Systematic Reviews;2022-02-28

2. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors;American Journal of Therapeutics;2018-03

3. Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study;Thrombosis and Haemostasis;2018-03

4. INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION;Rational Pharmacotherapy in Cardiology;2017-01-01

5. The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect;International Journal of Cardiology;2016-02